Shamsah Sonawalla, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antidepressive Agents, Second-Generation | 7 | 2010 | 489 | 0.550 |
Why?
|
| Fluoxetine | 7 | 2010 | 733 | 0.520 |
Why?
|
| Depressive Disorder | 6 | 2008 | 3728 | 0.330 |
Why?
|
| Antidepressive Agents, Tricyclic | 4 | 2003 | 432 | 0.280 |
Why?
|
| Anxiety Disorders | 4 | 2010 | 2720 | 0.250 |
Why?
|
| Depressive Disorder, Major | 11 | 2010 | 4761 | 0.230 |
Why?
|
| Patient Compliance | 3 | 2003 | 2690 | 0.220 |
Why?
|
| Thiazepines | 1 | 2003 | 30 | 0.210 |
Why?
|
| Patient Dropouts | 1 | 2002 | 412 | 0.180 |
Why?
|
| Cholesterol | 2 | 2003 | 2904 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2002 | 8002 | 0.130 |
Why?
|
| Anger | 2 | 2010 | 406 | 0.120 |
Why?
|
| Personality Inventory | 3 | 2010 | 1019 | 0.100 |
Why?
|
| Hostility | 1 | 2010 | 183 | 0.080 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2009 | 561 | 0.080 |
Why?
|
| Lepidium | 1 | 2008 | 8 | 0.080 |
Why?
|
| Chi-Square Distribution | 3 | 2002 | 3416 | 0.070 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 5 | 2004 | 1988 | 0.070 |
Why?
|
| Phytotherapy | 1 | 2008 | 296 | 0.060 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2008 | 357 | 0.060 |
Why?
|
| Nortriptyline | 1 | 2003 | 79 | 0.050 |
Why?
|
| Desipramine | 1 | 2002 | 182 | 0.050 |
Why?
|
| Lithium Chloride | 1 | 2002 | 82 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2006 | 518 | 0.050 |
Why?
|
| Receptors, Dopamine | 1 | 2002 | 296 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2002 | 208 | 0.050 |
Why?
|
| Docosahexaenoic Acids | 1 | 2008 | 908 | 0.050 |
Why?
|
| Drug Resistance | 2 | 2003 | 1596 | 0.040 |
Why?
|
| Somatoform Disorders | 1 | 2003 | 423 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 2002 | 1122 | 0.040 |
Why?
|
| Social Isolation | 1 | 2002 | 364 | 0.040 |
Why?
|
| Adult | 18 | 2010 | 221177 | 0.040 |
Why?
|
| Emigration and Immigration | 1 | 2002 | 397 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2002 | 635 | 0.040 |
Why?
|
| Middle Aged | 14 | 2010 | 220895 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2009 | 2751 | 0.040 |
Why?
|
| Triazoles | 1 | 2002 | 903 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2002 | 6228 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 2850 | 0.030 |
Why?
|
| India | 1 | 2003 | 2348 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2002 | 2645 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2008 | 2897 | 0.030 |
Why?
|
| Male | 17 | 2010 | 360804 | 0.030 |
Why?
|
| Age Factors | 2 | 2002 | 18395 | 0.030 |
Why?
|
| Female | 18 | 2010 | 392644 | 0.030 |
Why?
|
| Pilot Projects | 4 | 2009 | 8631 | 0.030 |
Why?
|
| Severity of Illness Index | 4 | 2004 | 15842 | 0.030 |
Why?
|
| Double-Blind Method | 4 | 2009 | 12341 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2009 | 6019 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2003 | 2775 | 0.020 |
Why?
|
| Health Status | 1 | 2004 | 4077 | 0.020 |
Why?
|
| Logistic Models | 2 | 2004 | 13255 | 0.020 |
Why?
|
| Comorbidity | 2 | 2003 | 10508 | 0.020 |
Why?
|
| Primary Health Care | 2 | 2004 | 4686 | 0.020 |
Why?
|
| Humans | 18 | 2010 | 761504 | 0.020 |
Why?
|
| Aged | 6 | 2004 | 169289 | 0.020 |
Why?
|
| Cognition | 1 | 2006 | 6990 | 0.020 |
Why?
|
| Plant Roots | 1 | 2008 | 117 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 353 | 0.020 |
Why?
|
| Libido | 1 | 2008 | 119 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2010 | 64680 | 0.020 |
Why?
|
| Psychometrics | 2 | 2010 | 3065 | 0.020 |
Why?
|
| Research Design | 1 | 2002 | 6180 | 0.020 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2008 | 189 | 0.020 |
Why?
|
| Mass Screening | 1 | 2002 | 5428 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2003 | 5092 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 10766 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 1667 | 0.020 |
Why?
|
| Adolescent | 5 | 2004 | 88319 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2008 | 498 | 0.010 |
Why?
|
| Depression | 1 | 2002 | 8124 | 0.010 |
Why?
|
| Prevalence | 3 | 2004 | 15732 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2008 | 1808 | 0.010 |
Why?
|
| Culture | 1 | 2004 | 623 | 0.010 |
Why?
|
| Panic Disorder | 1 | 2003 | 613 | 0.010 |
Why?
|
| California | 1 | 2004 | 1429 | 0.010 |
Why?
|
| Antimanic Agents | 1 | 2002 | 520 | 0.010 |
Why?
|
| Lipids | 1 | 2009 | 3341 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2003 | 54425 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 1755 | 0.010 |
Why?
|
| Thalamus | 1 | 2002 | 1045 | 0.010 |
Why?
|
| Brain | 1 | 2002 | 27112 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2003 | 1141 | 0.010 |
Why?
|
| Triglycerides | 1 | 2003 | 2461 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2004 | 1936 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 6055 | 0.010 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2003 | 1491 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 6310 | 0.010 |
Why?
|
| Piperazines | 1 | 2002 | 2523 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 8465 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2006 | 4481 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 3249 | 0.010 |
Why?
|
| Boston | 1 | 2002 | 9326 | 0.000 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2003 | 4575 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 20098 | 0.000 |
Why?
|